whitepaper
Poster: Antibodies for microglial activation states
Development of novel rabbit monoclonal antibodies to characterise microglial activation states in murine models of Alzheimer’s disease.
List view / Grid view
Proteomics
article
Five recent cell and gene therapy discoveries
This article highlights five of the latest findings using cell and gene therapy techniques that could be used in the development or design of new therapies.
whitepaper
Poster: Tumour-infiltrating immune cell markers
Need some direction in choosing immune cell markers? Whether you are working with human cells or a mouse model, CST has you covered!
news
Why are women more likely to get Alzheimer’s?
US researchers find that a modified immune protein harming brain connections is much more common in the brains of women with Alzheimer’s, compared to men.
article
Rapidly transitioning from in silico hits to leads on ‘undruggable’ pain targets
Opioid addiction is an ongoing crisis in the US. Researchers have identified a key regulator that shapes analgesic and aversive outputs of kappa opioid receptor signalling, finding lead inhibitors of this previously ‘undruggable’ target class – the Regulators of G protein Signalling (RGS proteins) – to help re-establish non-addictive kappa…
whitepaper
Article: Understanding potency in cell and gene therapy development
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
whitepaper
Article: Challenges in developing CAR T-cell therapies
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
whitepaper
Whitepaper: Correlate protein expression with genomic data and IHC
Measure protein, DNA and RNA in FFPE tissue samples using rigorously IHC validated CST antibodies on the NanoString® nCounter® platform.
news
The future of drug development: AI tailors artificial DNA
Swedish researchers have designed synthetic DNA that controls a cells’ protein production using AI.
video
Video: Proteomics solutions for drug discovery
Dr. Stokes, Associate Director Proteomics, discusses how proteomic studies can increase effectiveness, speed of target and biomarker identification.
whitepaper
Whitepaper: Unique solutions for drug discovery and development
Looking for solutions to resolve your unique challenges? We offer several customized products and services to move your discovery forward.
news
Novel synthetic peptides could suppress formation of harmful amyloid aggregates
German researchers have designed peptides that bind to amyloidogenic proteins linked to Alzheimer’s and type 2 diabetes, to effectively suppress both cytotoxic amyloid aggregation and amyloid cross-accelerating interactions.
whitepaper
Product hub: Targeted protein degradation – next-generation therapeutics
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
article
Synthetic biology is ready for the therapeutic limelight
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
article
T-cell redirecting bispecific antibodies: the next era of immune-based therapies for multiple myeloma?
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…